Trial Profile
Study of safety and efficacy of vedolizumab in patients with steroid refractory acute gastrointestinal graft-versus-host disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2018
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 27 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association